Cargando…

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma

Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil-Sierra, Manuel David, Briceño-Casado, Maria Del Pilar, Julia-Luna, Francisco Javier, Martinez-Moya, Maria Dolores
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Drug Watch
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846917/ https://www.ncbi.nlm.nih.gov/pubmed/36537407 http://dx.doi.org/10.4103/ijp.ijp_563_21

Ejemplares similares

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes
por: Akoglu, Gulsen
Publicado: (2014)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma
por: Das, Anupam, et al.
Publicado: (2014)

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Iula, R, et al.
Publicado: (2022)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
por: Popat, Rakesh, et al.
Publicado: (2023)

Hydroxychloroquine-induced erythroderma
por: Pai, Sunil B., et al.
Publicado: (2017)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

Belantamab mafodotin associated corneal microcyst-like epithelial changes
por: Chuang, Katherine, et al.
Publicado: (2022)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2021)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Rathi, Chetan, et al.
Publicado: (2021)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

Ageusia as a side effect of clopidogrel treatment
por: Ksouda, Kamilia, et al.
Publicado: (2011)

Immune reconstitution and inflammatory syndrome due to disseminated tuberculosis in a case of human immunodeficiency virus 2 infection
por: Subbalaxmi, M. V. S., et al.
Publicado: (2011)

Acute hepatic failure due to yellow phosphorus ingestion
por: Mauskar, Anupama, et al.
Publicado: (2011)

Flucytosine for treatment of Candida albicans in H1N1-positive patient
por: Samra, Tanvir, et al.
Publicado: (2010)

Sitagliptin-induced hemolysis
por: Bekur, Ragini, et al.
Publicado: (2010)

A case of paroxetine-induced galactorrhoea with normal serum prolactin level
por: Chakraborty, Suddhendu, et al.
Publicado: (2010)

Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010)

An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity?
por: Vasudevan, Biju
Publicado: (2010)

High anion gap refractory metabolic acidosis as a critical presentation of endosulfan poisoning
por: Sharma, Raj Kumar, et al.
Publicado: (2011)

Sodium artesunate-induced diuresis in a patient with malaria
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Cholestatic hepatitis with intravenous ceftriaxone
por: Kaur, Inderpal, et al.
Publicado: (2011)

Propofol-induced violent coughing in a patient with Becker's muscular dystrophy
por: Jain, Amit
Publicado: (2011)

Allopurinol-induced DRESS syndrome
por: Yaylacı, Selcuk, et al.
Publicado: (2012)

Norfloxacin-induced hypoglycemia and urticaria
por: Mishra, Ajay, et al.
Publicado: (2012)

Successful treatment of excessive dose of carbamazepine
por: Yaylacı, Selcuk, et al.
Publicado: (2012)

Cefditoren pivoxil associated rash and arthralgia in a child
por: Nandy, Manab, et al.
Publicado: (2012)

Unilateral tremor induced by risperidone in a patient with acute mania: Vitamin B12 deficiency as possible mediating factor
por: Kattimani, Shivanand, et al.
Publicado: (2012)

Paraphenylene diamine poisoning
por: Prabhakaran, A.C. Jesudoss
Publicado: (2012)

Quadriparesis and dysarthria due to tetrabenazine therapy in a child with rheumatic chorea
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_b7a1q5j4el9sjhnvcpkp97fcib